Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

Rate: Number of deaths due to prostate cancer per 100,000 male population.

Definition: Number of deaths per 100,000 males with malignant neoplasm (cancer) of the prostate as the underlying cause of death (ICD-10 code: C61).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

Every year numerous new cases of cancer are diagnosed in Italy. The figure presented refer to the share of specific tumors out of the total number of cancers diagnosed among males in 2020 and in 2022, when the data is available. According to the source, prostate cancer registered the highest incidence among males in 2022, with 19.8 percent, followed by lung tumor, with 15 percent.

From 2018 to 2022, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2018 and 2022, by age.

The proportion of deaths from prostate cancer (ICD-10 C61) that occur at home. To improve palliative care and service planning for cancer patients in the terminal stages of life, allowing more of them the choice of dying at home. Legacy unique identifier: P00771

BackgroundScreening for prostate cancer is frequent in high-income countries, including Switzerland. Notably due to overdiagnosis and overtreatment, various organisations have recently recommended against routine screening, potentially having an impact on incidence, mortality, and surgery rates. Our aim was therefore to examine whether secular trends in the incidence and mortality of prostate cancer, and in prostatectomy rates, have recently changed in Switzerland.MethodsWe conducted a population-based trend study in Switzerland from 1998 to 2012. Cases of invasive prostate cancer, deaths from prostate cancer, and prostatectomies were analysed. We calculated changes in age-standardised prostate cancer incidence rates, stratified by tumor stage (early, advanced), prostate cancer-specific mortality, and prostatectomy rates.ResultsThe age-standardised incidence rate of prostate cancer increased greatly in men aged 50–69 years (absolute mean annual change +4.6/100,000, 95% CI: +2.9 to +6.2) between 1998 and 2002, and stabilised afterwards. In men aged ≥ 70 years, the incidence decreased slightly between 1998 and 2002, and more substantially since 2003. The incidence of early tumor stages increased between 1998 and 2002 only in men aged 50–69 years, and then stabilised, while the incidence of advanced stages remained stable across both age strata. The rate of prostatectomy increased markedly until 2002, more so in the 50 to 69 age range than among men aged ≥ 70 years; it leveled off after 2002 in both age strata. Trends in surgery were driven by radical prostatectomy. Since 1998, the annual age-standardised mortality rate of prostate cancer slightly declined in men aged 50–69 years (absolute mean annual change -0.1/100,000, 95% CI: -0.2 to -0.1) and ≥ 70 years (absolute mean annual change -0.5/100,000, 95% CI: -0.7 to -0.3).ConclusionsThe increases in the incidence of early stage prostate cancer and prostatectomy observed in Switzerland among men younger than 70 years have concomitantly leveled off around 2002/2003. Given the decreasing mortality, these trends may reflect recent changes in screening and clinical workup practices, with a possible attenuation of overdiagnosis and overtreatment.

Years of life lost due to mortality from prostate cancer (ICD-10 C61). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00245

This summary brings together information on prostate cancer incidence, mortality and survival.

Source agency: Office for National Statistics

Designation: National Statistics

Language: English

Alternative title: Prostate cancer: the most common cancer in men in England

The incidence of prostate cancer among men in Sweden fluctuated during the period from 2008 to 2023. The highest incidence rate was in 2009 and 2014, when the rate was *** cases per hundred thousand inhabitants. In 2023, the rate was *** cases per hundred thousand inhabitants.

It was estimated that in 2025 around 313,780 men in the United States would develop prostate cancer. This statistic depicts the estimated number of new cancer cases among men in the U.S. in 2009 and 2025, by cancer type.

Prostate Cancer Market Outlook

The global prostate cancer market size is projected to experience significant growth over the forecast period, with an estimated market value of approximately USD 15.4 billion in 2023 and anticipated to reach around USD 25.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.3%. This growth is primarily driven by the increasing prevalence of prostate cancer across the globe, advancements in diagnostic technology, and the continuous development of novel treatment options. A rising geriatric population, which is more susceptible to prostate cancer, further catalyzes the market expansion. Awareness programs and increased healthcare spending are also pivotal in propelling market growth during the forecast period.

One of the primary growth factors in the prostate cancer market is the rising incidence of prostate cancer cases. This is attributable to both improved diagnostic techniques and the increasing awareness among men regarding prostate health. The adoption of regular screening practices such as Prostate-Specific Antigen (PSA) testing has led to earlier detection and consequently more treatment options, bolstering market growth. Furthermore, there is an ongoing effort in the medical community to establish more efficient and less invasive diagnostic procedures, which could make screening more accessible and appealing to a broader audience, thereby increasing the potential patient pool for treatment.

Technological advancements in treatment methods also play a crucial role in the market's growth. The development and approval of newer therapies such as targeted therapy and immunotherapy have transformed the prostate cancer treatment landscape, providing patients with more personalized and effective treatment options. The significant progress in precision medicine and an enhanced understanding of genetic and molecular markers associated with prostate cancer have paved the way for more targeted treatments, which not only improve patient outcomes but also lead to the market's robust expansion. Moreover, continuous research and clinical trials are vital in discovering new drugs and therapies that could potentially enhance the existing treatment paradigms for prostate cancer.

Prostate Cancer Screening plays a pivotal role in the early detection and management of prostate cancer. Regular screening, such as Prostate-Specific Antigen (PSA) testing, has significantly contributed to identifying the disease at an earlier stage, which is crucial for effective treatment. Early detection through screening not only increases the chances of successful treatment but also reduces mortality rates associated with prostate cancer. As awareness about the benefits of regular screening grows, more men are opting for these preventive measures, thereby expanding the potential patient pool for treatment and driving market growth. The integration of advanced screening techniques is expected to further enhance early diagnosis, making prostate cancer screening an indispensable component of prostate health management.

The growing investment in healthcare infrastructure in emerging economies is another critical factor contributing to the market's growth. Countries in the Asia Pacific and Latin America regions are witnessing a surge in healthcare investments, facilitating better access to cancer treatment and advanced medical facilities. This increased investment has also led to an upsurge in the number of hospitals and cancer research institutes, which are pivotal end-users in the prostate cancer treatment market. Moreover, government initiatives aimed at improving healthcare access and affordability for cancer patients are expected to further augment the market's growth trajectory, particularly in regions with historically limited access to advanced cancer care.

Regionally, North America currently holds the largest share of the prostate cancer market, driven by a high prevalence of the disease, advanced healthcare infrastructure, and substantial research funding in oncology. However, Asia Pacific is projected to exhibit the highest growth rate during the forecast period, fueled by economic development, increasing healthcare awareness, and a growing patient base. Europe also presents a significant market share due to a well-established healthcare system and ongoing research into innovative cancer treatments. In contrast, regions like Latin America and the Middle East & Africa are expected to witness moderate growth, constrained by economic and infrastructural challenges, though imp

In 2021, only 26 percent of survey respondents who were aged 50 to 64 years had a prostate-specific antigen (PSA) test that screened for prostate cancer in the past year. Prostate cancer is the most common type of cancer among men in the United States. This statistic shows the percentage of men aged 50 years and older who had a prostate cancer test in the U.S. in the past year as of 2021, by age.

Mortality from prostate cancer (ICD-10 C61 equivalent to ICD-9 185). To reduce deaths from prostate cancer. Legacy unique identifier: P00626

Rate or HR for PSA testing, prostate biopsies, prostate biopsies in men with elevated PSA, and prostatitis diagnosis.

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/no...

Prostate Cancer Diagnostics Market Outlook

As per our latest research, the global prostate cancer diagnostics market size reached USD 5.43 billion in 2024, demonstrating robust growth driven by technological advancements and increased awareness of early cancer detection. The market is expected to expand at a CAGR of 11.2% from 2025 to 2033, projecting a value of USD 14.54 billion by 2033. This significant growth is primarily fueled by the rising prevalence of prostate cancer globally, the adoption of next-generation diagnostic modalities, and the integration of artificial intelligence (AI) in clinical workflows.

One of the primary growth factors in the prostate cancer diagnostics market is the increasing incidence rate of prostate cancer, particularly among aging male populations in developed and emerging economies. According to the World Health Organization, prostate cancer remains the second most commonly diagnosed cancer in men worldwide, accounting for a substantial proportion of cancer-related morbidity and mortality. This alarming trend has compelled healthcare systems to prioritize early detection and efficient diagnostic protocols, thereby driving demand for advanced prostate cancer diagnostics solutions. Furthermore, higher awareness campaigns and screening programs initiated by governments and non-profit organizations have further amplified the adoption of diagnostic tests, especially in high-risk demographics.

Another significant driver is the rapid technological evolution in diagnostic methodologies. The transition from conventional diagnostic methods, such as digital rectal exams, to more sophisticated molecular and genetic testing has profoundly enhanced the accuracy and reliability of prostate cancer detection. Innovations such as liquid biopsy, next-generation sequencing, and AI-powered diagnostic imaging have enabled clinicians to identify prostate cancer at earlier stages, tailor treatments, and monitor disease progression with greater precision. These advancements not only improve patient outcomes but also reduce the burden of unnecessary biopsies and overtreatment, making them increasingly attractive to both healthcare providers and patients.

The market is also benefiting from the expanding role of personalized medicine in oncology. With a growing understanding of the genetic and molecular underpinnings of prostate cancer, diagnostic companies are developing targeted assays and companion diagnostics that enable individualized risk assessment and therapy selection. This trend is particularly evident in the integration of biomarkers such as PCA3, TMPRSS2-ERG, and circulating tumor cells (CTCs) into routine clinical practice. The convergence of genomics, proteomics, and digital health technologies is expected to further revolutionize the prostate cancer diagnostics landscape, opening new avenues for precision diagnostics and patient-centric care.

From a regional perspective, North America continues to dominate the global prostate cancer diagnostics market, owing to its well-established healthcare infrastructure, high rate of cancer screening, and strong presence of leading diagnostic companies. However, Asia Pacific is emerging as a lucrative region due to its rapidly aging population, increasing healthcare expenditure, and growing awareness about early cancer detection. Europe also holds a significant share, supported by favorable reimbursement policies and robust research initiatives. Meanwhile, Latin America and the Middle East & Africa are witnessing gradual market penetration, propelled by ongoing healthcare reforms and international collaborations aimed at improving cancer diagnostics accessibility.

Product Type Analysis

The prostate cancer diagnostics market by product type is segmented into instruments, consumables & reagents, and accessories. Instruments play a pivotal role in the diagnostic workflow, encompassing advanced imaging systems, automated analyzers, and biopsy devices. The continuous development of high-resolution imaging modalities, su

Numbers are medians (5–95% percentiles) unless otherwise specified1Socioeconomic position of municipalities based on municipality information on education, work market affiliation and incomeBaseline characteristics of the 24,473 male participants in the Diet, Cancer and Health cohort by prostate cancer status.

This statistic shows the rate of registrations of newly diagnosed cases of prostate cancer per 100,000 population in England in 2020, by region. With a rate of 160.2 newly diagnosed males with prostate cancer per 100,000 population in 2020, the region most affected by prostate cancer was South East.

Note: RSS = 56233.7; AICc = 10010.2; Adjusted R2 = 0.3892Model fit statistics suggest that the GWR model fit our data better than the OLS model. Comparing the GWR model to the OLS model, RSS and AICc were lower, and the Adjusted R2 was higher with GWR.Intercept estimates are non-zero because mean-centering was done globally, not locally.Range of Coefficient Estimates in the Multivariate Geographically Weighted Regression of County Level Prostate Cancer Mortality Rates (per 100,000 men).

Hazard ratios for the association of different factors with an incident prostate cancer diagnosis.